Wissenschaftliche Arbeiten
Doç. Dr. Zeynep Yegin Katran
60 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.
-
Use of omalizumab in chemotherapy rapid drug desensitization: Can anaphylaxis be prevented?
Allergy, 2023
Quelle: ORCID
-
Successful Treatment of Tuberculosis Combined With Rifampicin Induced Interstitial Nephritis: A Case Report
International Journal of Nephrology and Kidney Failure, 2023
DOI 10.16966/2380-5498.235 Frei zugänglicher VolltextQuelle: OpenAlex
-
Dahili Hastalarda Özel Beslenme ve Diyet Yönetimi
Akademisyen Kitabevi eBooks, 2022
DOI 10.37609/akya.2182 Quelle: OpenAlex
-
Management of type 1 hypersensitivity reactions to antituberculosis drug: Succesful Desensitization
Research Square, 2022
DOI 10.21203/rs.3.rs-1752643/v1 Frei zugänglicher VolltextQuelle: ORCID
-
Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization
Allergy Asthma and Clinical Immunology, 2022
DOI 10.1186/s13223-022-00737-4 PMID 36414980 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID
-
Successful Oxaliplatin Desensitization After Omalizumab Administration
Research Square, 2022
DOI 10.21203/rs.3.rs-2313500/v1 Frei zugänglicher VolltextQuelle: ORCID
-
Treatment and Management of Hypersensitivity Reactions Developed Against Anti-Tuberculosis Drug
International Journal of Mycobacteriology, 2022
DOI 10.4103/ijmy.ijmy_78_22 PMID 36260451 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID
-
Tuberculosis Treatment-related Lichenoid Drug Eruptions
International Journal of Mycobacteriology, 2022
DOI 10.4103/ijmy.ijmy_151_22 PMID 36510939 Frei zugänglicher VolltextQuelle: ORCID
-
The predictive value of qSOFA and CURB-65 scores in predicting the hospitalization need and mortality in patients with acute exacerbation of chronic obstructive pulmonary disease
Italian Journal of Emergency Medicine, 2021
DOI 10.23736/s2532-1285.20.00039-7 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex
-
Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk
The Clinical Respiratory Journal, 2018
DOI 10.1111/crj.12726 PMID 29028148 17 Zitationen (Europe PMC) Quelle: ORCID